Key Details
Price
$239.76Last Dividend
$0.27Annual ROE
9.20%Beta
0.69Events Calendar
Next earnings date:
Jan 30, 2025Recent quarterly earnings:
Oct 22, 2024Recent annual earnings:
Jan 30, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
Sept 27, 2024Next split:
N/ARecent split:
Oct 02, 2023Analyst ratings
Recent major analysts updates
Screeners with DHR included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
On November 26, 2024, Danaher Corporation (NYSE: DHR) shared that their President and CEO, Rainer M. Blair, will speak at the Evercore ISI HealthCONx Conference. This event will take place in Coral Gables, Florida, on Wednesday, December 4, 2024, at 3:25 p.m.
Danaher announced decent earnings for the third quarter, and "cautious" is likely the best word to describe the report. The company is back to growing, and their future outlook appears positive, but the management is hesitant to provide specific figures to support their optimism. I discuss the possible reasons for this cautious approach in the article.
On Tuesday, Danaher Corp DHR announced that its sales for the third quarter reached $5.79 billion, which is a 3% increase compared to the same period last year. This figure surpassed the expected consensus of $5.59 billion.
DHR's earnings and sales for the third quarter exceeded expectations, thanks to the strong results from its Life Sciences and Diagnostics divisions.
The Danaher Corporation (NYSE:DHR) held its Q3 2024 Earnings Call on October 22, 2024, at 8:00 AM ET. Key participants included John Bedford, the VP of Investor Relations, Rainer Blair, the President and CEO, and Matt McGrew, the EVP and CFO. The call was facilitated by Ashley, who welcomed everyone to the conference.
Danaher (DHR) reported quarterly earnings of $1.71 per share, which is higher than the Zacks Consensus Estimate of $1.56 per share. This is a decrease compared to earnings of $2.02 per share from the same period last year.
On Tuesday, Danaher exceeded Wall Street's expectations for its third-quarter profits due to high demand in its diagnostics and bioprocessing sectors, as well as growth in its molecular testing division.
On October 22, 2024, Danaher Corporation (NYSE: DHR) shared its financial results for the quarter that ended on September 27, 2024. This announcement focuses solely on the company's ongoing operations, unless stated otherwise.
Instead of just focusing on Wall Street's predictions for Danaher (DHR), it's important to examine some of its key metrics to better understand how the company might perform in the quarter that ended in September 2024. This deeper analysis can provide valuable insights into its potential success.
DHR is expected to gain from the strong performance of its clinical diagnostics division, the acquisition of Abcam, and policies that favor shareholders. However, there are still worries about the weaker performance of the Instrument unit.
FAQ
- What is the primary business of Danaher?
- What is the ticker symbol for Danaher?
- Does Danaher pay dividends?
- What sector is Danaher in?
- What industry is Danaher in?
- What country is Danaher based in?
- When did Danaher go public?
- Is Danaher in the S&P 500?
- Is Danaher in the NASDAQ 100?
- Is Danaher in the Dow Jones?
- When was Danaher's last earnings report?
- When does Danaher report earnings?
- Should I buy Danaher stock now?